Philadelphia Medical Weight-Loss FAQs

Eligibility depends on BMI, weight-related conditions, history, current medicines, contraindications and the product’s indication. A clinician must assess the individual.

No. Semaglutide or tirzepatide may be considered for some patients, while another medication or a non-medication plan may be safer, more affordable or better aligned with preferences.

No. W8MD requires the first Philadelphia visit to be conducted in person.

Coverage is plan-specific. Benefits, exclusions, prior authorization, formularies, copayments and deductibles apply. Coverage cannot be guaranteed.

Potential effects differ by medication. With GLP-1–based treatment, gastrointestinal symptoms are common concerns; severe or persistent abdominal pain, repeated vomiting, dehydration or other alarming symptoms require prompt medical attention. Review the specific prescribing information with the clinician.

There is no guaranteed rate. Results depend on treatment, adherence, biology, starting point, dose, tolerability, sleep, activity and other factors. Clinically meaningful improvements can occur without reaching an “ideal” number.

The plan can emphasize adequate protein, resistance activity when appropriate, reasonable calorie targets and body-composition monitoring. Individual needs vary.

Yes. Snoring, witnessed pauses, morning headaches or daytime sleepiness may prompt sleep evaluation. Weight loss may improve some patients’ sleep apnea but should not replace PAP or other prescribed treatment without reassessment.

The clinician reviews intake, adherence, sleep, activity, medicines, adverse effects and expectations before deciding whether to continue, adjust or change the strategy.

Maintenance is part of responsible obesity care. Plans may address continued medication when appropriate, nutrition, activity, relapse prevention and transitions if coverage changes.